HealthLinx Ltd, 576 Swan Street, Richmond, Victoria 3121, Australia.
Clin Sci (Lond). 2010 Mar 30;118(12):717-25. doi: 10.1042/CS20090537.
Ovarian cancer is often asymptomatic and is diagnosed at an advanced stage with poor survival rates, thus there is an urgent need to develop biomarkers for earlier detection of ovarian cancer. In the present study, we demonstrate for the first time that the previously reported metastasis-inducing protein AGR2 (anterior gradient protein 2) can be detected in the blood of ovarian cancer patients. Using a newly developed ELISA, we show significantly increased concentrations of AGR2 protein in plasma from cancer patients relative to normal controls. Plasma AGR2 concentrations were highest in stages II and III ovarian cancer patients and were similarly elevated in patients with both serous and non-serous tumours. The identification of elevated plasma concentrations of AGR2 may provide a useful biomarker to aid in the discrimination of normal and ovarian cancer patients particularly when used in combination with CA125.
卵巢癌通常无症状,在晚期诊断,生存率较差,因此迫切需要开发生物标志物以早期检测卵巢癌。在本研究中,我们首次证明先前报道的转移诱导蛋白 AGR2(前梯度蛋白 2)可在卵巢癌患者的血液中检测到。使用新开发的 ELISA,我们显示与正常对照相比,癌症患者血浆中的 AGR2 蛋白浓度显着增加。在 II 期和 III 期卵巢癌患者中,血浆 AGR2 浓度最高,在浆液性和非浆液性肿瘤患者中也同样升高。AGR2 血浆浓度升高的鉴定可能提供有用的生物标志物,有助于区分正常和卵巢癌患者,特别是与 CA125 联合使用时。